Dehydroepiandrosterone reduces preadipocyte proliferation via androgen receptor

American Journal of Physiology - Endocrinology and Metabolism

Volumn 302, Issue 6, 2012, Pages 694-704

  Fujioka, Kei ^a   Kajita, Kazuo ^a   Wu, Zhiliang ^a   Hanamoto, Takayuki ^a   Ikeda, Takahide ^a   Mori, Ichiro ^a   Okada, Hideyuki ^a   Yamauchi, Masahiro ^a   Uno, Yoshihiro ^a   Morita, Hiroyuki ^a   Nagano, Isao ^a   Takahashi, Yuzo ^a   Ishizuka, Tatsuo ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adipocyte growth; Testosterone

Indexed keywords

ANDROGEN RECEPTOR; BETA GALACTOSIDE; BROXURIDINE; ESTROGEN RECEPTOR; FLUTAMIDE; FULVESTRANT; PRASTERONE; TESTOSTERONE;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL DIVISION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DNA DETERMINATION; EPIDIDYMIS FAT; IN VITRO STUDY; IN VIVO STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROADIPOCYTE; RAT; WEIGHT REDUCTION;

ADIPOCYTES; ADIPOSITY; ANIMALS; ANTIMETABOLITES; BETA-GALACTOSIDASE; BLOOD VESSELS; BLOTTING, WESTERN; BROMODEOXYURIDINE; CELL AGING; CELL PROLIFERATION; CELL SHAPE; CELLS, CULTURED; CHROMOSOMAL INSTABILITY; DEHYDROEPIANDROSTERONE; DNA DAMAGE; GLYCEROL; MALE; RATS; RATS, INBRED OLETF; RATS, LONG-EVANS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ANDROGEN; STROMAL CELLS; TESTOSTERONE; TRIGLYCERIDES;

EID: 84858213498     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00112.2011     Document Type: Article

References (57)

1. Barrett-Connor E, Khaw KT, Yen SS. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med 315: 1519-1524, 1986.
2. Barrett-Connor E, Goodman-Gruen D. Dehydroepiandrsterone sulfate does not predict cardiovascular death in postmenopausal women. Circulation 91: 1757-1760, 1995.
3. Berdanier CD, Parente JA Jr, Mcintosh MK. Is dehydroepiandrosterone an antiobesity agent? FASEB J 7: 414-419, 1993.
4. Biouin K, Richard C, Brochu G, Hould FS, Lebel S, Marceau S, Biron S, Luu-The V, Tchernof A. Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men. J Endocrinol 191: 637-649, 2006.
5. Bolduc C, Larose M, Yoshioka M, Ye P, Belleau P, Labrie C, Morissette J, Raymond V, Labrie F, St-Amand J. Effects of dihydrotestosterone on adipose tissue measured by serial analysis of gene expression. J Mol Endocrinol 33: 429-444, 2004.
6. Buffington CK, Givens JR, Kitabchi A. Opposing action of dehydroepiandrosterone and testosterone on insulin sensititivy. Diabetes 40: 693-700, 1991.
7. Callies F, Fassnacht M, Christoph van Vlijmen J, Koehler I, Huebler D, Seibel MJ, Arlt W, Allolio B. Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity. J Clin Endocrinol Metab 86: 1968-1972, 2001.
8. Calvo E, Luu-The V, Morisssette J, Martel C, Labrie C, Bernard B, Bernerd F, Deloche C, Chaussade V, Leclaire J, Labrie F. Pangenomic change induced by DHEA in the skin of postmenopausal women. J Steroid Biochem Mol Biol 112: 186-193, 2008.
9. Coleman DL, Leiter EH, Schwizer RW. Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice. Diabetes 31: 830-833, 1982.
10. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20: 284-287, 1998.
11. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubeli I, Pereira-Smith O, Peacocke M. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92: 9363-9367, 1995.
12. Enomoto M, Adachi H, Fikami A, Furuki K, Satoh A, Otsuka M, Kumagae S, Nanjo Y, Shigetoh Y, Imaizumi T. Serum dehydroepiandrosterone sulfate levels predict longevity in men: 27-year follow-up study in a community-based cohort (Tanushimaru study). J Am Geriatr Soc 56: 994-998, 2008.
13. Fan W, Yanase T, Nomura M, Okabe T, Goto K, Sato T, Kawano H, Kato S, Nawata H. Androgen receptor null mice develop late-oncet obesity caused by decreased energy expenditure and lipolytic activity but show normal insulin sensitivity with high adiponectin secretion. Diabetes 54: 1000-1008, 2005.
14. Folch J, Lees M, Sloane-Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226: 497-509, 1957.
15. Henderson GC, Dhatariya K, Ford GC, Klaus KA, Basu R, Rizza RA, Jenson MD, Khosla S, O'Brin P, Nair KS. Higher muscle protein synthesis in women than men across the lifespan, and failure of androgen administration to amend age-related decrements. FASEB J 23: 631-641, 2009.
16. Hiragun A. Cell and tissue culture models of adipocyte development. In: New Perspective in Adipose Tissue: Structure, Function and Development. Cryer A, Van RLR, eds. London: Butterworths, 1985, p. 333-352.
17. Howard E. Dehydroepiandrosterone and testosterone: comparative androgenic potencies and contrasting actions. Endocrinology 72: 19-27, 1963.
18. Howard E. Steroids and bone maturation in infant mice: relative activities of dehydroepiandrosterone and testosterone. Endocrinology 70: 131-141, 1962.
19. Ikeda T, Kajita K, Zhiliang W, Hanamoto T, Mori I, Fujioka K, Okada H, Fujikake T, Uno Y, Morita H, Nagano I, Takahashi Y, Ishizuka T. Effects of phorbol ester-sensitive PKC (c/nPKC) activation on the production of adiponectin in 3T3-L1 adipocytes. IUBMB Life 61: 644-650, 2009.
20. Ishizuka T, Kajita K, Miura A, Ishizawa M, Kanoh Y, Itaya S, Kimura M, Muto N, Mune T, Morita H, Yasuda K. DHEA improves glucose uptake via activation of protein kinase C and phosphatidylinositol 3-kinase. Am J Physiol Endocrinol Metab 276: E196-E203, 1999.
21. Kajita K, Ishizuka T, Mune T, Miura A, Ishizawa M, Kanoh Y, Kawai Y, Natsume Y, Yasuda K. Dehydroepiandrosterone down-regulates the expression of peroxisome proliferators-activated receptor γ in adipocytes. Endocrinology 144: 253-259, 2003.
22. Kapoor D, Malkin CJ, Channer KS, Jones TH. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol 63: 239-250, 2005.
23. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 154: 899-906, 2006.
24. Kapoor D, Channer KS, Aldred H, Jones TH, Clark S. Clinical and biological assessment of hypogonadism in men with type 2 diabetes. Diabetes Care 30: 911-917, 2007.
25. Karbowska J, Kochan Z. Effect of DHEA on endocrine functions of adipose tissue, the involvement of PPARγ. Biochem Pharmacol 70: 249-257, 2005.
26. Kochakian CD. A comparison of the renotrophic with the androgenic activity of various steroids. Am J Physiol 142: 315-325, 1944.
27. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T, Eto K, Tsubamoto Y, Okuno A, Murakami K, Sekihara H, Hasegawa G, Naito M, Toyoshima Y, Tanaka S, Shiota K, Kitamura T, Fujita T, Ezaki O, Aizawa S, Kadowaki T. PPARgamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4: 597-609, 1999.
28. Labrie C, Belanger A, Labrie F. Androgenic activity of dehydroepiandrosterone and androstendione in rat ventral prostate. Endocrinology 123, 1412-1417, 1988.
29. Labrie F. Intracrinology. Mol Cell Endocrinol 78: C113-C118, 1991.
30. Labrie F, Luu-The V, Bélanger A, Lin SX, Simard J, Pelletier G, Labrie C. Is dehydroepiandrosterone a hormone? J Endocrinol 187: 169-196, 2005.
31. Lea-Currie YR, Wen P, Macintosh MK. Dehydroepiandrosterone reduces proliferation and differentiation of 3T3-L1 preadipocytes. Biochem Biophys Res Commun 248: 497-504, 1998.
32. Lee K, Villena JA, Moon YS, Kim KH, Lee S, Kang C, Sul HS. Inhibition of adipogenesis and development of glucose intolerance by soluble preadipocyte factor-1. J Clin Invest 111: 453-461, 2003.
33. McIntosh M, Hausman D, Martin R, Hausman G. Dehydroepiandrosterone attenuates preadipocyte growth in primary culture of stromalvascular cells. Am J Physiol 38: E285-E293, 1998.
34. Oberbeck R, Kobbe P. Dehydroepiandrosterone (DHEA): a steroid with multiple effects. Is there any possible option in the treatment of critical illness? Curr Med Chem 17: 1039-1047, 2010.
35. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 59: 551-555, 1984.
36. Pirke KM, Doerr P. Age related changes in interrelationships between plasma testosterone, oestradiol and testosterone binding globulin in normal adult males. Acta Endocrinol 74: 792-800, 1973.
37. Planat-Benard V, Silvestre JS, Cousin B, André Nibbelink M, Tamarat R, Clergue M, Manneville C, Saillan-Barreau C, Duriez M, Tedgui A, Levy B, Pénicaud L, Casteilla L. Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. Circulation 109: 656-663, 2004.
38. Rice SPL, Zhang L, Grennan-Jones F, Agarwal N, Lewis MD, Rees DA, Ludgate RM. Dehydroepiandrosterone (DHEA) treatment in vitro inhibits adipogenesis in human omental but not subcutaneous adipose tissue. Mol Cell Endocrinol 320: 51-57, 2010.
39. Rodriguez-Cuenca S, Monjo M, Gianotti M, Proenza M, Roca P. Expression of mitochondrial biogenesis-signaling factors in brown adipocytes is influenced specifically by 17β-estradiol, testosterone, and progesterone. Am J Physiol Endocrinol Metab 292: E340-E346, 2007.
40. Rosen ED, MacDougald OA. Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol 7: 885-896, 2006.
41. Roth GS, Lane MA, Ingram DK, Mattison JA, Elahi D, Tobin JD, Muller D, Metter EJ. Biomarkers of caloric restriction may predict longevity in humans. Science 297: 811, 2002.
42. Sato K, Iemitsu M, Aizawa K, Ajisaka R. Testosterone and DHEA activate the glucose metabolism-related signaling pathway in skeletal muscle. Am J Physiol Endocrinol Metab 294: E961-E968, 2008.
43. Sato T, Matsumoto T, Yamada T, Watanabe T, Kawano H, Kato S. Late onset of obesity in male androgen receptor-deficient (AR KO) mice. Biochem Biophys Res Commun 300: 167-171, 2003.
44. Schriock ED, Buffington CK, Hubert GD, Kurtz BR, Kitabchi AE, Buster JE, Givens JR. Divergent correlations of circulating dehydroepiandrosterone sulfate and testosterone with insulin levels and insulin receptor binding. J Clin Endocrinol Metab 66: 1329-1331, 1988.
45. Schulz S, Klann RC, Schonfeld S, Nyce JW. Mechanism of cell growth inhibition and cell cycle arrest in human colonic adenocarcinoma cells by dehydroepiandrosterone: role of isoprenoid biosynthesis. Cancer Res 57: 1372-1376, 1992.
46. Shilkaitis A, Green A, Punj V, Steele V, Lubet R, Christov K. Dehydroepiandrosterone inhibits the progression phase of mammary carcinogenesis by inducing cellular senescence via a p16-dependent but p-53-independent mechanism. Breast Cancer Res 7: R1132-R1140, 2005.
47. Sikora E, Arendt T, Bennett M, Narita M. Impact of cellular senescence signature on aging research. Aging Res Rev 10: 146-152, 2011.
48. Tchernof A, Despres JP, Dupont A, Belanger A, Nadeau A, Prud'homme D, Moorjani S, Lupien PJ, Labrie F. Relation of steroid hormones to glucose tolerance and plasma insulin levels in men. Importance of visceral adipose tissue. Diabetes Care 18: 292-299, 1995.
49. Tchernof A, Labrie F. Dehydroepiandrosterone, obesity and cardiovascular disease risk: a review of human studies. Eur J Endocrinol 151: 1-14, 2004.
50. Tian WN, Braunstein LD, Pang JP, Stuhlmeier KM, Xi QC, Tian X, Stanton RC. Importance of glucose-6-phosphate dehydrogenase activity for cell growth. J Biol Chem 273: 10609-10617, 1998.
51. Valle LD, Toffolo V, Nardi A, Fiore C, Bernante P, Di Liddo R, Parnigotto PP, Colombo L. Tissue-specific transcriptional initiation and activity of steroid sulfatase complementing dehydroepiandrosterone sulfate uptake and intracrine steroid activations in human adipose tissue. J Endocrinol 190: 129-139, 2006.
52. Villareal DT, Holloszy JO, Kohrt WM. Effect of DHEA replacement on bone mineral density and body composition in elderly women and men. Clin Endocrinol 53: 561-568, 2000.
53. Wang C, Eyre DR, Clark R, Kleinberg D, Newman C, Iranmanesh A, Veldhuis J, Dudley RE, Berman N, Davidson T, Barstow TJ, Sinow R, Alexander G, Swerdloff RS. Sublingual testosterone replacement improves muscle mass and bone formation markers in hypogonadal men-a clinical research center study. J Clin Endocrinol Metab 81: 3654-3662, 1996.
54. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112, 1796-1808, 2003.
55. Xu X, De Pergola G, Björntorp P. The effects of androgens on the regulation of lipolysis in adipose precursor cells. Endocrinology, 126: 1229-1239, 1990.
56. Yamauchi T, Waki H, Kamon J, Murakami K, Motojima K, Komeda K, Miki H, Kubota N, Terauchi Y, Tsuchida A, Kasaoka N, Yamauchi N, Ide T, Hori W, Kato S, Fukayama M, Akanuma Y, Ezaki O, Itai K, Nagai R, Kimura S, Tobe K, Kagechika H, Shudo K, Kadowaki T. Inhibition of RXR and PPARγ ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest 108: 1001-1013, 2001.
57. Yoshida S, Honda A, Matsuzaki Y, Fukushima S, Tanaka N, Takagiwa A, Fujimoto Y, Miyazaki H, Salen G. Anti-proliferative action of endogenous dehydroepiandrosterone metabolites on human cancer cell lines. Steroids 68: 73-83, 2003.